FCAR/CD89 Antibody (488032) [Alexa Fluor® 488]

• Reactivity: Hu, Pm-Cm
• Applications: Flow
• Clone: 488032
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 488
• Concentration: Please see the vial label for concentration. If unlisted please contact technical services.

FCAR/CD89 Antibody (488032) [Alexa Fluor® 488] Summary

• Immunogen: NS0 mouse myeloma cell line transfected with human FCAR/CD89
  Gln22-Lys287
  Accession # P24071
• Specificity: Detects human FCAR/CD89 in direct ELISAs. Detects human and cynomolgus monkey FCAR/CD89 in Flow cytometry. In direct ELISAs, no cross-reactivity with Fc gamma RIA, RIIA, or RIIIB is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: FCAR
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25-1 ug/10^6 cells
• Application Notes: Flow Cytometry: Please use 0.25-1 ug of conjugated antibody per 10e6 cells.

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.
• Preservative: 0.09% Sodium Azide
• Concentration: Please see the vial label for concentration. If unlisted please contact technical services.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FCAR/CD89 Antibody (488032) [Alexa Fluor® 488]

• CD89 antigen
• CD89
• CD89IgA Fc receptor
• Fc alpha receptor
• Fc fragment of IgA, receptor for
• FCAR
• immunoglobulin alpha Fc receptor

Background

FCAR, also called Fc alpha RI or CD89, is a variably glycosylated 50‑100 kDa myeloid-specific type I transmembrane (TM) Fc receptor for IgA that is a member of the multichain immune recognition receptor (MIRR) family (1‑3). Human FCAR contains a 21 amino acid (aa) signal sequence and extracellular (ECD), TM and cytoplasmic domains of 206, 19 and 41 aa, respectively (4). Arg230 within the TM domain supports interaction with the ITAM-containing signaling subunit, FcR gamma , which contains a TM Asp (5‑7). Two ECD C2-type Ig-like domains (EC1 and 2) are oriented at right angles (8). Up to two molecules of FCAR can bind one molecule of serum IgA via EC1 (8). Many splice variants have been reported, but only two have been identified as proteins (9, 10). The a.2 form, which lacks 22 aa just prior to the TM domain, is exclusively expressed in alveolar macrophages. The a.3 form lacks EC2. FCAR binds monomeric, polymeric and secretory IgA, but does not mediate the barrier function of secretory IgA in mucosal epithelium (1‑3). Shedding and circulation of polymeric IgA/FCAR immune complexes has been reported (11). Circulating neutrophils, eosinophils, and monocytes express FCAR (12). Tissue expression of FCAR is mainly from neutrophils; FCAR is downregulated as monocytes differentiate to tissue macrophages (12). On neutrophils, a significant amount of FCAR lacks FcR gamma , but can still be endocytosed to early endosomes and recycled to the cell surface (5). Binding of serum IgA to FCAR is transient and anti-inflammatory, inhibiting IgG or IgE-induced degranulation (6). Sustained aggregation of FCAR results in inflammatory responses (6). FcR gamma signaling is required for these and for transport to late endosomes (5‑7). Human FCAR shows 55‑58% aa identity with rat, horse and cow FCAR. No ortholog occurs in mouse. FCAR structure resembles the KIR/ILT/LIR/MIR family more than other IgA receptors, including pIgR, Fc alpha /μR, asialoglycoprotein receptor (ASGR1) and transferrin receptor (TfR) (1‑3).

1. Wines, B. D. and P. M. Hogarth (2006) Tissue Antigens 68:103.
2. Otten, M. A. and M. van Egmon (2004) Immunol. Lett. 92:23.
3. Montiero, R. C. and J. G. J. van de Winkel (2003) Annu. Rev. Immunol. 21:177.
4. Maliszewski, C. R. et al. (1990) J. Exp. Med. 172:1665.
5. Launay, P. et al. (1999) J. Biol. Chem. 274:7216.
6. Pasquier, B. et al. (2005) Immunity 22:31.
7. Shen, L. et al. (2001) Blood 97:205.
8. Herr, Y. et al. (2003) Nature 423:614.
9. Patry, C. et al. (1996) J. Immunol. 156:4442.
10. Togo, S. et al. (2003) FEBS Lett. 535:205.
11. van der Boog, P. J. M. et al. (2002) J. Immunol. 168:1252.
12. Hamre, R. et al. (2003) Scand. J. Immunol. 57:506.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for FCAR/CD89 Antibody (FAB3939G)(1)

Publication using FAB3939G

• AT Björklund, M Carlsten, E Sohlberg, LL Liu, T Clancy, M Karimi, S Cooley, JS Miller, M Klimkowska, M Schaffer, E Watz, KI Wikstrom, P Blomberg, BE Wahlin, M Palma, L Hansson, P Ljungman, E Hellström-, HG Ljunggren, KJ Malmberg Complete Remission with Reduction of High-risk Clones following Haploidentical NK Cell Therapy against MDS and AML Clin. Cancer Res., 2018-02-14;0(0):. 2018-02-14 [PMID: 29444931] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: FCAR
• Uniprot:
  • P24071()